Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > Looks good to me

<< Previous

Bullboard Posts

Next >>

Comment by Stockmoneyman17on Dec 05, 2020 9:30am

162 Views

Post# 32043567

RE:RE:Looks good to me

Also look up Jed wood. He was a director for Hemo back in 2016, same time as Kyle Makofka You think these boys don't no anything about the product Hemo has? This was the group who tried to take it over

IMO

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter